Eli Lilly and Company (LLY): A Long Term Stock to Buy

Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy. On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver.

Eli Lilly and Company (LLY) A Long Term Stock to Buy on hypercholesterolemia Treatment Progress

The trial results show that VERVE-102 successfully reduced PCSK9 by up to 88% and LDL-C by up to 62%. The investigational drug was well tolerated across all dose levels, with no related adverse events or dose-limiting toxicities. The top-line results indicate that the candidate drug could offer a novel approach for achieving substantial and durable LDL-C reduction with a one-time treatment.

Eli Lilly senior vice president and co-founder of Verve Therapeutics, Sekar Kathiresan, insists the trial results affirm that a single dose of VERVE-102 may mimic the LDL-C-lowering effects of PCSK9 cardioprotective variants. Consequently, it could transform cardiovascular care from chronic management to one-time treatment.

The US Food and Drug Administration has already granted Fast Track designation for VERVE-102 for the reduction of LDL-C in participants with hyperlipidemia and high lifetime cardiovascular risk.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader that discovers, develops, and manufactures innovative prescription medicines. The company focuses on breakthrough treatments for critical conditions, primarily in cardiometabolic diseases (diabetes and obesity), oncology, immunology, and neuroscience.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Best 52-Week High Stocks to Invest In According to Short Sellers and 15 Best Micro and Small Cap Stocks to Buy According to Jim Simons’ Renaissance Technologies.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1